Knuff & Co LLC Boosts Stock Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Knuff & Co LLC grew its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 9.8% during the 4th quarter, Holdings Channel reports. The firm owned 10,126 shares of the company’s stock after buying an additional 900 shares during the period. Knuff & Co LLC’s holdings in GE HealthCare Technologies were worth $792,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Ashton Thomas Securities LLC purchased a new position in GE HealthCare Technologies during the third quarter worth approximately $26,000. Capital Performance Advisors LLP acquired a new position in shares of GE HealthCare Technologies in the 3rd quarter valued at about $26,000. Darwin Wealth Management LLC acquired a new position in shares of GE HealthCare Technologies in the 3rd quarter valued at about $31,000. Continuum Advisory LLC grew its position in GE HealthCare Technologies by 101.8% in the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after purchasing an additional 168 shares during the last quarter. Finally, Bank of Jackson Hole Trust bought a new position in GE HealthCare Technologies in the 4th quarter worth about $32,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

GE HealthCare Technologies Trading Up 0.3 %

Shares of GEHC stock opened at $85.59 on Wednesday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.83 and a current ratio of 1.04. The company has a market capitalization of $39.14 billion, a price-to-earnings ratio of 19.77, a PEG ratio of 3.19 and a beta of 1.13. GE HealthCare Technologies Inc. has a 52-week low of $74.51 and a 52-week high of $94.80. The company has a 50-day simple moving average of $87.06 and a two-hundred day simple moving average of $86.17.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The firm had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.33 billion. Research analysts anticipate that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

Analyst Ratings Changes

GEHC has been the subject of a number of research analyst reports. The Goldman Sachs Group raised shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and upped their price target for the stock from $85.00 to $100.00 in a research note on Tuesday. Wells Fargo & Company raised their target price on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Citigroup increased their price target on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Finally, Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their price objective for the stock from $95.00 to $103.00 in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, GE HealthCare Technologies has a consensus rating of “Moderate Buy” and an average price target of $98.75.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.